Detect biomarkers associated with Nonalcoholic Fatty Liver Disease (NAFLD)
Using the SomaScan® Assay to identify new biomarkers in liver disease
Abstract
In this 1-hour discussion, learn how the SomaScan Assay can be used to detect biomarkers associated with NAFLD—specifically, the identification of circulating proteins associated with fibrosis in NAFLD using a custom 5k-plex SomaScan Assay. Also discussed is the importance of identifying non-invasive biomarkers that improve clinical decision-making and drug development for NAFLD, and the strategies for multiplexed validation of candidate biomarkers discovered using the SomaScan Assay.
Kathleen Corey, MD, MPH, MMSc
Director of the Massachusetts General Hospital NAFLD program and an Assistant Professor of Medicine at Harvard Medical School
Rebecca Pitts
Principal scientist at the Novartis Institutes for BioMedical Research in Cambridge, Massachusetts
Advancing biomarkers for Nonalcoholic Fatty Liver Disease using proteomics
A webinar presented by Kathleen Corey, MD, MPH, MMSc, and Rebecca Pitts
More webinars
WebinarAccelerating precision medicine of cancer with SomaScan® proteomics
Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.
WebinarImproving clinical development productivity with high-plex proteomics
While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete. Assessment of the human proteome is thus increasingly recognized as a priority for successful and cost-effective drug development and clinical research.
WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic Technologies can give your research programs an edge